Updated:
Saama Technologies
Saama Technologies, led by Suresh Katta, uses AI and analytics to accelerate clinical trials for pharmaceutical firms.
Saama Technologies
Saama Technologies was founded by Suresh Katta, who serves as CEO. The firm occupies a niche in life sciences data analytics, focusing on clinical trial acceleration. It has not publicly disclosed wealth origin or ownership structure, typical of a privately held analytics firm. The firm targets pharmaceutical and biotech organizations, offering analytics solutions that compress trial timelines. Its asset-class mix is entirely focused on technology services and software, with no disclosed deployment in funds or alternative assets. Geographically, Saama operates primarily in North America, with reported clients across the US and Europe. Named portfolio companies or co-investors are not publicly listed, as the firm appears to function as a service provider rather than an investment vehicle. Team size and additional offices are not publicly documented. Saama has not disclosed any adjacent philanthropic or operating-company structures. Recent activity includes ongoing work with top pharmaceutical firms, but no specific dated event from the last 24 months is on public record. The firm’s structural differentiator lies in its specialized focus on clinical trial analytics, a regulated market with high barriers to entry. Unlike generalist data firms, Saama operates within FDA-compliant frameworks, giving it a defensible niche. Its model prioritizes service revenue over capital deployment, distinguishing it from most family offices or asset managers.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Campbell
Corporate office
Campbell, CA, United States
Sector focus
Frequently asked questions
Who runs investment decisions at Saama Technologies?
CEO Suresh Katta leads the firm. Saama has not disclosed a separate investment committee or CIO, as it operates as a technology services company rather than an investment firm.
How does Saama Technologies source proprietary deal flow?
Saama does not source investment deal flow. It wins contracts through direct sales to pharmaceutical and biotech organizations, competing based on its analytics platform and domain expertise (per public record).
Is Saama Technologies structured as a single family office or does it operate more like a venture firm?
Saama is a privately held technology company, not a family office or venture firm. Its revenue model is service-based, not fund-based.
Does Saama Technologies participate in fund commitments or only direct deals?
The firm does not participate in fund commitments or direct investments. It serves clients through software and consulting contracts.
What investment stages does Saama Technologies typically target?
Not applicable. Saama is not an investment firm; it provides analytics services across the drug development lifecycle.
Where does the underlying wealth come from?
Saama Technologies has not disclosed its ownership structure or wealth origin. It is privately held and does not publicly list shareholders.
Does Saama Technologies maintain philanthropic structures?
There is no public information about philanthropic structures associated with Saama Technologies.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: